Patent · US Active

High purity oritavancin and method of producing same

US10328118B2 · kind B2 · utility

0Cited by

5References

10Claims

0Family size

Assignees

MELINTA THERAPEUTICS, INC. · US
Abb Vie Inc. · US

Inventors

Adel Rafai Far · Montréal, CA
Gopal Krishna · Dover, US
Min Ding · Dobbs Ferry, US
Sanjay R. Chemburkar · Gurnee, US
Carl M. Knable · North Chicago, US
James P. Petzel · North Chicago, US
Julie J. Pruyne · Gurnee, US
Douglas M. Reamer · North Chicago, US

Key dates

Filing date	Feb 22, 2017
Grant date	Jun 25, 2019
Priority date	—
Expiry date	Feb 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12P21/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.